Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kestra Medical Technologies (KMTS) Shares Outstanding (Diluted Average) (2024 - 2026)

Kestra Medical Technologies (KMTS) has disclosed Shares Outstanding (Diluted Average) for 3 consecutive years, with $55.8 million as the latest value for Q1 2026.

  • Quarterly Shares Outstanding (Diluted Average) rose 180.85% to $55.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $55.8 million through Jan 2026, up 180.85% year-over-year, with the annual reading at $24.6 million for FY2025, 23.63% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q1 2026 was $55.8 million at Kestra Medical Technologies, up from $51.3 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $55.8 million in Q1 2026, with the low at $19.9 million in Q1 2024.
  • Average Shares Outstanding (Diluted Average) over 3 years is $31.4 million, with a median of $19.9 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Diluted Average) changed 0.0% in 2025, then soared 180.85% in 2026.
  • Over 3 years, Shares Outstanding (Diluted Average) stood at $19.9 million in 2024, then soared by 158.18% to $51.3 million in 2025, then increased by 8.78% to $55.8 million in 2026.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $55.8 million, $51.3 million, and $51.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.